Abstract
Based upon phase I and II studies of deferoxamine alone and in combination with cytotoxic agents cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT), we initiated a single arm multicentre trial in 1992 for advanced neuroblastoma. 57 of 65 patients who entered the trial were evaluable. Following 4 courses of the D-CECaT, almost all the patients underwent surgery. Toxicity was moderate and mainly reversible myelosuppression. The post-surgically defined responses in stage 3 high risk, stage 4 moderate risk and stage 4 high risk patients included 24 complete responses, 26 partial responses, and 3 minor responses, and 4 patients had progressive disease. These patients are being followed to determine the impact of this programme on their overall survival.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Adolescent
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Chemotherapy, Adjuvant
-
Child
-
Child, Preschool
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Deferoxamine / administration & dosage
-
Deferoxamine / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Humans
-
Infant
-
Neoplasm Staging
-
Neuroblastoma / drug therapy*
-
Neuroblastoma / pathology
-
Neuroblastoma / surgery
-
Risk Factors
-
Thiotepa / administration & dosage
-
Thiotepa / adverse effects
Substances
-
Etoposide
-
Cyclophosphamide
-
Thiotepa
-
Carboplatin
-
Deferoxamine